The practice of registering therapeutic clinical trials in a publically accessible database has been slowly gaining momentum over the last 2 decades. This is either a cause for celebration or frustration, depending upon whether one places the emphasis on ''gaining momentum'' or ''slowly.'' The term clinical trial is commonly applied to prospective experimental studies that allocate participants randomly to 1 or more therapeutic interventions or a control group. The International Committee of Medical Journal Editors (ICMJE) somewhat more expansively defines a clinical trial as ''any research project that prospectively assigns people to an intervention, with or without concurrent comparison or control groups.'' 9 In the United States (US), the Food and Drug Administration Modernization Act of 1997 (FDAMA 113) mandated the establishment of ClinicalTrials.gov, a government-sponsored website that debuted in 2000. 18 A number of other trials registries offer researchers a variety of choices for publicly posting their study plan. 5, 31 The cause of clinical trial registration has been promoted by professional organizations such as the ICJME, World Medical Association, 32 and World Health Organization, 31 and, perhaps more effectively, by government legislation. 1, 6, 18, 26, 30 A decade after the FDAMA required registration of trials involving serious diseases such as cancer, the Food and Drug Administration Act of 2007 (FDAAA) mandated registration and public outcome disclosure for US trials of drugs, including biological products, and medical devices. 18, 30, 33 Important exemptions were granted for early-stage trials of new agents. In the European Union, the 2001 Clinical Trials Directive stipulates similar requirements for drugs and biologics. 4 The proposed US Trials and Experimental Studies (TEST) Act would expand the reporting requirements to include more outcomes information and trials outside the US. 11, 18 The concept of clinical trial registration initially focused on treatments for cancer and other serious diseases. 24 Public registration of trials, it was reasoned, would directly benefit patients desperately seeking an experimental treatment that offered hope for conditions with limited conventional options. 5 Matching suitable patients with ongoing trials might not only help them personally, but, by facilitating the enrollment of subjects, hasten the completion of the studies and thus potentially speed the delivery of therapeutic advances to many more afflicted individuals.
Beyond its ability to benefit individual trials and their participants, however, another important goal of trial registration is to minimize bias against publication of negative studies, thus improving the validity of the medical literature and reducing duplication of unsuccessful treatment efforts. 11, 26 Numerous studies have shown that research with negative or inconclusive results is less likely to be published, most commonly because it is never submitted for publication. 12, 17, 23 As a consequence, reviews limited to published literature are more likely to determine a positive effect for a treatment than if both published and unpublished trials are tabulated. 24 Prospective registration of all clinical trials, if comprehensive, would theoretically make all such studies, even those abandoned before completion or completed but never published, accessible for inclusion in systematic reviews and meta-analyses. Public trial registration can also conserve finite research funds by minimizing unwitting replication of trials already in progress. 5 Unfortunately, the realization of this apparently straightforward scenario has been stymied at a number of points. Despite various guidelines or legislation encouraging or requiring registration at the time a trial is initiated, compliance is far from universal. Trial registration may be incomplete, tardy, or not occur at all. 8, 13, 27, 28 A 2012 study of randomized controlled trials (RCTs) published in 121 core Medline journals found that 39% did not appear to have been registered, 27 while a 2011 sampling of trials registered in ClinicalTrials.gov revealed that more than half were only registered after enrollment had begun. 28 Leading medical journals have a better track record than this, although even they have taken time to get up to speed. A 2013 study of articles published in 2010-2011 in 5 ICJME founding journals found that 96% reported a registration identification number. 8 Although only 60% of the trials were registered within 60 days of enrolling the first patient, compliance with this criterion had improved over time, rising to 89% for studies registered in 2008. 8 Even when trials are registered, their results may never be published. One might expect a high publication rate for studies financed by major funding agencies, yet a 2012 review of trials funded by the US National Institutes of Health (NIH) reported that only 46% had appeared in a journal within 30 months of completion. 22 After a median follow-up of 51 months, 32% still remained unpublished. Among registered orthopaedic trials, the publication rate has been reported as 22.8% for arthroplasty-related studies, 25 38.9% for spine, 16 43.2% for trauma, 7 and 58.8% for sports medicine. 2 Unpublished studies are still able or required to post their principal results in ClinicalTrials.gov and other databases. 19 This is not as desirable as journal publication, because this information has not gone through peer review, but certainly preferable to no publication at all. In any case, authors of registered trials frequently neglect to post their results in a registry. In 2011, Prayle et al 19 reported that among 738 trials registered on Clinical-Trials.gov that were required by the FDAAA to post results within 12 months of publication, only 22% had complied. This meager rate was impressive only in comparison with the 10% rate for trials that did not fall under the legal mandate. In a more recent publication, Jones et al 10 examined 585 registered trials with 500 or more participants. Among the 171 (29%) of these large studies that remained unpublished about 4 years after completion, only 38 (22%) had results available on ClinicalTrials.gov. The authors estimated that 250,000 individuals had entered into a study whose results were not publically accessible.
Registration and journal publication do not guarantee that the study report has not been tweaked to spin its message in a desired, usually positive direction. 5 Deviations from the original experimental design, such as selecting a different follow-up period, varying the number of included participants, changing the primary outcome measure, or selectively reporting measures that show a positive effect are all ways to favor desired conclusions. 3, 14, 21 The strengths of prospective study design are undercut if it is retrofitted in this manner. Registration prior to enrolling the first patient discourages such practices by making them discoverable, although this behavior may still occur. 14 Prospective public registration of clinical trials and publishing or posting their results on a timely basis are clearly desirable goals, yet surveys have shown that a substantial percentage of researchers and journal editors are reluctant to endorse them completely. 12, 20, 29 Existing legislation requiring prompt posting of results is incompletely enforced. 10, 19 All stakeholders can work harder to improve this performance. The editorial boards of The American Journal of Sports Medicine and our open access affiliate, The Orthopaedic Journal of Sports Medicine, have recently taken steps in this direction. Previously, AJSM policy has been to encourage but not absolutely mandate registration of clinical trials. At its last meeting, the AJSM editorial board voted to require prospective registration for all randomized trials commenced after December 31, 2015. The OJSM editorial board recently voted to accept for peer review and publication articles that report the design of a proposed clinical trial. This option will give investigators a chance to refine their study design prior to commencement according to the comments of peer reviewers and to supplement registry posting in a citable OJSM publication. While these unilateral initiatives won't guarantee the universal registration and reporting of clinical trials in orthopaedic sports medicine, we hope that they will help accelerate the gathering momentum towards that goal.
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